One of the most notable achievements of 2023 was the approval of a disease-modifying Alzheimer’s drug, representing a breakthrough in the decades-long quest to combat this debilitating condition. Developed by Eisai and Biogen, the amyloid-fighting antibody Leqembi offers hope to millions affected by Alzheimer’s and their families. Moreover, the approval of Leqembi reflects a renewed focus on addressing complex neurological disorders, signaling a shift towards tackling previously untreatable conditions.
The FDA’s approval landscape in 2023 also highlighted the growing prominence of biologic therapies, with nearly half of the newly approved drugs falling into this category. This trend underscores the increasing utilization of advanced biologic modalities and the expanding capabilities of biotechnology in addressing diverse medical needs. Furthermore, the approval of multiple orphan drugs for rare diseases emphasizes the importance of targeted therapies in addressing unmet medical needs within smaller patient populations.
Despite the remarkable progress made in 2023, the FDA faced challenges such as delays due to COVID-19-related constraints and contentious decision-making processes. However, the agency’s commitment to advancing public health and fostering innovation remained steadfast, paving the way for a new era of medical breakthroughs. As we look ahead to 2024, anticipation mounts for further advancements in drug development and the potential for additional groundbreaking therapies to transform patient care and improve outcomes across a spectrum of diseases.
https://www.nature.com/articles/s41587-024-02166-7
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services